JP2020531002A - 獣医学用ｉｇｇ ｆｃ変異体 - Google Patents

獣医学用ｉｇｇ ｆｃ変異体 Download PDF

Info

Publication number
JP2020531002A
JP2020531002A JP2020507675A JP2020507675A JP2020531002A JP 2020531002 A JP2020531002 A JP 2020531002A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A JP2020531002 A JP 2020531002A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
igg
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531002A5 (enExample
Inventor
ハンチュン チャン，
ハンチュン チャン，
ラム グェン，
ラム グェン，
ヨンチョン リー，
ヨンチョン リー，
フォーン チエン，
フォーン チエン，
シー ジアン リー，
シー ジアン リー，
Original Assignee
キンドレッド バイオサイエンシズ インコーポレイテッド
キンドレッド バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020531002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by キンドレッド バイオサイエンシズ インコーポレイテッド, キンドレッド バイオサイエンシズ インコーポレイテッド filed Critical キンドレッド バイオサイエンシズ インコーポレイテッド
Publication of JP2020531002A publication Critical patent/JP2020531002A/ja
Publication of JP2020531002A5 publication Critical patent/JP2020531002A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020507675A 2017-08-15 2018-08-15 獣医学用ｉｇｇ ｆｃ変異体 Pending JP2020531002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545858P 2017-08-15 2017-08-15
US62/545,858 2017-08-15
PCT/IB2018/056142 WO2019035010A1 (en) 2017-08-15 2018-08-15 IGG VARIANTS FOR VETERINARY USE

Publications (2)

Publication Number Publication Date
JP2020531002A true JP2020531002A (ja) 2020-11-05
JP2020531002A5 JP2020531002A5 (enExample) 2021-09-30

Family

ID=65361820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507675A Pending JP2020531002A (ja) 2017-08-15 2018-08-15 獣医学用ｉｇｇ ｆｃ変異体

Country Status (10)

Country Link
US (1) US12297272B2 (enExample)
EP (1) EP3668536A4 (enExample)
JP (1) JP2020531002A (enExample)
KR (1) KR20200057701A (enExample)
CN (2) CN119390821A (enExample)
AU (3) AU2018318440A1 (enExample)
BR (1) BR112020002871A2 (enExample)
CA (1) CA3071337A1 (enExample)
MX (1) MX2020001707A (enExample)
WO (1) WO2019035010A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612112B (zh) 2016-12-09 2024-03-29 阿卡斯通生物科学公司 胰岛素-fc融合物及使用方法
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
DK4186920T5 (da) 2018-06-29 2024-07-22 Akston Biosciences Corp Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
BR112021006977A2 (pt) * 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
MX2021007680A (es) * 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
MX2021008144A (es) * 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
CN113840831A (zh) * 2019-03-20 2021-12-24 金德雷德生物科学股份有限公司 医用ngf拮抗剂
JP2022542275A (ja) * 2019-07-30 2022-09-30 キンドレッド バイオサイエンシズ インコーポレイテッド 動物用パルボウイルス抗体
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230348577A1 (en) 2020-02-19 2023-11-02 Adivo Gmbh Modified fc regions
WO2021188631A1 (en) * 2020-03-18 2021-09-23 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
BR112022020486A2 (pt) 2020-04-10 2023-01-17 Akston Biosciences Corp Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso
JP2023524643A (ja) * 2020-04-22 2023-06-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための長時間作用性抗ｉｌ３１抗体
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4149969A1 (en) 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
AU2021306179A1 (en) 2020-07-10 2023-03-02 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
WO2022046809A1 (en) * 2020-08-24 2022-03-03 The Trustees Of The University Of Pennsylvania Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
KR20250130357A (ko) 2022-12-27 2025-09-01 인베티엑스 인코포레이티드 신생아 fc 수용체 (fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181912A1 (en) * 2005-07-27 2009-07-16 Qinghua Wang GLP/1/EXENDIN 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2010533197A (ja) * 2007-07-10 2010-10-21 イーライ リリー アンド カンパニー ＧＬＰ−１−Ｆｃ融合タンパク質配合物
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene
US7297482B2 (en) * 1998-10-08 2007-11-20 Rigel Pharmaceuticals, Inc. Structurally biased random peptide libraries based on different scaffolds
WO2001047950A2 (en) * 1999-12-23 2001-07-05 Universite De Geneve Basolateral sorting signal based on scf peptide and inhibitors thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
AU2009329866B2 (en) * 2008-12-23 2016-09-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein A
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
RU2012145183A (ru) * 2010-03-29 2014-05-10 Займворкс, Инк. Антитела с повышенной или пониженной эффекторной функцией
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
US9353172B2 (en) 2011-07-18 2016-05-31 Arts Biologics A/S Long acting biologically active luteinizing hormone (LH) compound
US9416168B2 (en) 2011-07-19 2016-08-16 The National Institute for Biotechnology in the Negev, Ltd IL-17R-ECD mutants and methods of using same
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
KR102052774B1 (ko) * 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN104159916A (zh) * 2012-02-22 2014-11-19 Nvip私人有限公司 肿瘤坏死因子受体融合蛋白及其使用方法
ES2746103T3 (es) 2012-04-30 2020-03-04 Medimmune Llc Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2880057A4 (en) 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
WO2014093387A1 (en) 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20250152665A (ko) 2013-07-31 2025-10-23 암젠 인크 Ｆc-함유 폴리펩타이드의 안정화
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
US20170182154A1 (en) 2014-01-22 2017-06-29 Beijing Advaccine Biotechnology Co. Ltd Vaccines with interleukin-17 as an adjuvant
CN106687135A (zh) 2014-09-15 2017-05-17 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
EP3215524B1 (en) * 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
EP3365011A1 (en) 2015-10-19 2018-08-29 Novartis AG Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
JP6890135B2 (ja) 2016-01-26 2021-06-18 ディフェンシン セラピューティクス エーピーエス 腸内微生物叢を調節するための方法
EP3416984B1 (en) * 2016-02-18 2021-03-31 Elanco US Inc. Chimeric canine anti-cd20 antibody
AU2017268469C1 (en) 2016-05-20 2025-01-02 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
CN110267674A (zh) 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
CN110799210A (zh) 2016-12-02 2020-02-14 得克萨斯A&M大学系统 选择性消耗抗原特异性抗体的融合蛋白
CA3059731A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
CA3065553A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. Il17a antibodies and antagonists for veterinary use
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
DK4186920T5 (da) 2018-06-29 2024-07-22 Akston Biosciences Corp Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
US20220049002A1 (en) 2018-09-14 2022-02-17 Kindred Biosciences, Inc. Anti-IL4 Receptor Antibodies for Veterinary Use
BR112021006977A2 (pt) 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
EP3892632A4 (en) 2018-12-05 2022-08-17 Bica Therapeutics Inc. MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODIES
CN113423721A (zh) 2018-12-12 2021-09-21 金德雷德生物科学股份有限公司 兽用促红细胞生成素类似物
MX2021007680A (es) 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
MX2021008144A (es) 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
CN113840831A (zh) 2019-03-20 2021-12-24 金德雷德生物科学股份有限公司 医用ngf拮抗剂
CN114599389A (zh) 2019-08-22 2022-06-07 奇达拉治疗公司 变体fc结构域及其用途
WO2021043127A1 (zh) 2019-09-02 2021-03-11 甘李药业股份有限公司 嵌合蛋白
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230242635A1 (en) 2020-04-17 2023-08-03 Zoetis Services Llc Canine antibody variants
BR112022020631A2 (pt) 2020-04-17 2022-11-29 Zoetis Services Llc Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula
JP2023524643A (ja) 2020-04-22 2023-06-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための長時間作用性抗ｉｌ３１抗体
CA3173927A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Il4/il13 receptor molecules for veterinary use
EP4149969A1 (en) 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2021251438A1 (ja) 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
WO2022005883A1 (en) 2020-06-29 2022-01-06 Zoetis Services Llc Feline antibody variants for improving stability
AU2021306179A1 (en) 2020-07-10 2023-03-02 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
EP4204013A4 (en) 2020-08-26 2025-04-16 Angiex, Inc. ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181912A1 (en) * 2005-07-27 2009-07-16 Qinghua Wang GLP/1/EXENDIN 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2010533197A (ja) * 2007-07-10 2010-10-21 イーライ リリー アンド カンパニー ＧＬＰ−１−Ｆｃ融合タンパク質配合物
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, vol. Vol.61, p.209-230, JPN6022038064, 2009, ISSN: 0005021855 *
MOLECULAR IMMUNOLOGY, vol. Vol.45, p.818-827, JPN6022038068, 2008, ISSN: 0005021858 *
PROTEIN ENGINEERING, vol. vol.16, p.243-245, JPN6022038066, 2013, ISSN: 0005021854 *
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. vol.157, p.31-41, JPN6022038065, 2014, ISSN: 0005021856 *
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. vol.158, p.214-223, JPN6022038067, 2014, ISSN: 0005021857 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント

Also Published As

Publication number Publication date
CN119390821A (zh) 2025-02-07
AU2018318440A1 (en) 2020-02-13
RU2020110584A3 (enExample) 2021-12-15
AU2023226676A1 (en) 2023-09-28
RU2020110584A (ru) 2021-09-17
AU2023226676B2 (en) 2025-05-22
EP3668536A1 (en) 2020-06-24
MX2020001707A (es) 2020-03-20
WO2019035010A1 (en) 2019-02-21
BR112020002871A2 (pt) 2020-07-28
CA3071337A1 (en) 2019-02-21
KR20200057701A (ko) 2020-05-26
US12297272B2 (en) 2025-05-13
US20200362034A1 (en) 2020-11-19
CN111182915A (zh) 2020-05-19
EP3668536A4 (en) 2021-05-26
AU2025220819A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
JP2020531002A (ja) 獣医学用ｉｇｇ ｆｃ変異体
JP6960832B2 (ja) Ｆｇｆ２１突然変異体及びその使用
US8835385B2 (en) FGF21 polypeptides comprising two or more mutations and uses thereof
US20250092115A1 (en) Igg fc variants for veterinary use
JP6040464B2 (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN103732628A (zh) 多价杂多聚体骨架设计和构建体
US20220169740A1 (en) NGF Antagonists for Medical Use
KR20230005880A (ko) 수의학적 사용을 위한 il4/il13 수용체 분자
KR20250057131A (ko) 수의학 용도를 위한 il4/il13 수용체 분자
RU2814952C2 (ru) ВАРИАНТЫ IgG-FC ДЛЯ ПРИМЕНЕНИЯ В ВЕТЕРИНАРИИ
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения
HK40060829A (en) Igg fc variants for veterinary use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107